BiotechTube

DS-6000a + DS-6000a

Phase 1Active
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Renal Cell Carcinoma

Conditions

Renal Cell Carcinoma, Ovarian Tumor

Trial Timeline

Dec 22, 2020 → Jun 30, 2026

NCT ID
NCT04707248

About DS-6000a + DS-6000a

DS-6000a + DS-6000a is a phase 1 stage product being developed by Daiichi Sankyo for Renal Cell Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT04707248. Target conditions include Renal Cell Carcinoma, Ovarian Tumor.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04707248Phase 1Active

Competing Products

20 competing products in Renal Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109MBX BiosciencesPhase 1
28
LY3473329Eli LillyPhase 1
33
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
TildacerfontSpruce BiosciencesPhase 2
44
Drotrecogin alfa activated (Xigris)Eli LillyPhase 2
52
LY3819469Eli LillyPhase 1
33
Atezolizumab + CabozantinibChugai PharmaceuticalPhase 3
77
DS-1093aDaiichi SankyoPhase 1
33
CS-3150Daiichi SankyoPhase 3
77
AGS-16C3FAstellas PharmaPhase 1
33
AGS-16M8FAstellas PharmaPhase 1
33
CP-461Astellas PharmaPhase 2
52
roxadustatAstellas PharmaPhase 3
77
YM178Astellas PharmaPhase 1
33
intravenous immunoglobulins (IVIG)Astellas PharmaPhase 1
33
bixalomerAstellas PharmaPre-clinical
23
ASP8825Astellas PharmaPhase 1
33

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85